Nuvalent, Inc. (NASDAQ:NUVL) Short Interest Down 23.2% in November
Nuvalent, Inc. (NASDAQ:NUVL) Short Interest Down 23.2% in November
Nuvalent, Inc. (NASDAQ:NUVL – Get Rating) was the recipient of a large decrease in short interest in November. As of November 15th, there was short interest totalling 2,550,000 shares, a decrease of 23.2% from the October 31st total of 3,320,000 shares. Based on an average daily volume of 340,400 shares, the short-interest ratio is presently 7.5 days. Currently, 6.0% of the shares of the company are short sold.
新价公司(纳斯达克：NUVL-GET Rating)是11月份空头股数价格大幅下降的接受者。截至11月15日，空头股数共有255万股，比10月31日的332万股减少了23.2%。以日均成交量340,400股计算，目前短息比率为7.5天。目前，该公司6.0%的股份被卖空。
Nuvalent Price Performance
平价性价比
NASDAQ:NUVL traded up $1.69 on Thursday, hitting $34.57. The company had a trading volume of 14,072 shares, compared to its average volume of 314,159. The firm has a 50 day moving average of $25.43 and a two-hundred day moving average of $18.07. Nuvalent has a 52 week low of $7.09 and a 52 week high of $40.43.
纳斯达克：周四，NUVL股价上涨1.69美元，至34.57美元。该公司的成交量为14,072股，而其平均成交量为314,159股。该公司的50日移动均线切入位在25.43美元，200日移动均线切入位在18.07美元。现货价位为7.09美元，为52周低点，52周高点为40.43美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Separately, BMO Capital Markets increased their price objective on shares of Nuvalent from $28.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, October 28th.
另外，BMO Capital Markets在10月28日(星期五)的一份研究报告中将Nuvalal的股票目标价从28.00美元上调至50.00美元，并给予该公司“买入”评级。
Insiders Place Their Bets
内部人士下注
Hedge Funds Weigh In On Nuvalent
对冲基金对Nuvalal的看法
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Nuvalent by 115.6% in the 1st quarter. Vanguard Group Inc. now owns 1,637,507 shares of the company's stock valued at $22,745,000 after acquiring an additional 877,835 shares during the period. Fairmount Funds Management LLC increased its position in Nuvalent by 46.3% in the 1st quarter. Fairmount Funds Management LLC now owns 1,338,393 shares of the company's stock valued at $18,590,000 after acquiring an additional 423,779 shares during the period. BlackRock Inc. increased its position in Nuvalent by 30.2% in the 1st quarter. BlackRock Inc. now owns 1,257,463 shares of the company's stock valued at $17,466,000 after acquiring an additional 291,821 shares during the period. Millennium Management LLC acquired a new position in Nuvalent in the 2nd quarter valued at approximately $3,523,000. Finally, Driehaus Capital Management LLC increased its position in Nuvalent by 20.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,402,451 shares of the company's stock valued at $19,017,000 after acquiring an additional 242,383 shares during the period. Institutional investors own 95.07% of the company's stock.
机构投资者和对冲基金最近增持或减持了该股。先锋集团在第一季度增持了115.6%的纽瓦尔股份。先锋集团在此期间增持了877,835股，目前持有1,637,507股该公司股票，价值22,745,000美元。Fairmount Funds Management LLC在第一季度将其在Nuvality的头寸增加了46.3%。Fairmount Funds Management LLC在此期间额外收购了423,779股，目前拥有1,338,393股该公司的股票，价值18,590,000美元。贝莱德股份有限公司在第一季度增持了30.2%的纽瓦利股份。贝莱德股份有限公司在此期间增持了291,821股，目前持有该公司1,257,463股股票，价值17,466,000美元。千禧管理公司在第二季度收购了Nuvalal公司的一个新职位，价值约为3,523,000美元。最后，Driehaus Capital Management LLC在第二季度将其在Nuvality的头寸增加了20.9%。Driehaus Capital Management LLC在此期间额外收购了242,383股，目前拥有1,402,451股该公司的股票，价值19,017,000美元。机构投资者持有该公司95.07%的股票。
About Nuvalent
关于努瓦莱尔
(Get Rating)
(获取评级)
Nuvalent, Inc, a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.
新价公司是一家临床阶段的生物制药公司，为癌症患者开发疗法。其主要候选产品有NVL-520，这是一种脑穿透性ROS1选择性抑制剂，用于抑制ROS1融合，这种融合表达正常的ROS1激活域，没有任何耐药突变，并且在存在对已批准和正在研究的ROS1抑制剂产生耐药性的突变时仍保持活性，该药处于I期开发中；以及NVL-655，一种脑渗透性ALK选择性抑制剂，用于解决紧急治疗耐药性、中枢神经系统相关不良事件和脑转移等临床挑战，这些挑战可能限制正在进行I/II期临床试验的第一、第二和第三代ALK抑制剂的使用。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Nuvalent (NUVL)
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
- 免费获取StockNews.com关于Nuvalal的研究报告(NUVL)
- 卖空者对马伦汽车股票的看法仍然正确吗？
- La-Z-Boy倾斜到更舒适的水平
- 苹果会在年底前大涨吗？
- 复苏集会是为SoFi而来的吗？
- 放宽Covid规则会降低中国电动汽车制造商蔚来的风险吗？
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.
接受《新价日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Nuvalal及相关公司评级的每日简要摘要。